Atrioventricular Block After EVOQUE Transcatheter Tricuspid Valve Replacement
Recommended Citation
Rangavajla G, Patel R, Nguyen F, Vickers B, Abdelhai O, La Starza B, Ilg K, Maskoun W, Ebinger M, Lahiri M, Khan A, Greenberg J, Fram G, Alrayes H, Lok Lai LK, Wyman J, Parikh S, Zweig B, Dawdy J, Bowerman N, Engel Gonzalez P, O'Neill W, Villablanca P, Lee J, O'Neill BP, Raad M, and Frisoli TM. Atrioventricular Block After EVOQUE Transcatheter Tricuspid Valve Replacement. Struct Heart 2025;9(9):100701.
Document Type
Article
Publication Date
9-1-2025
Publication Title
Struct Heart
Abstract
•Based on a real-world study of 106 Evoque transcatheter tricuspid valve replacement (TTVR) recipients, a total of 14 (25%) cases of new atrioventricular (AV) block occurred after Evoque implantation in the 55 patients without prior pacemakers who met study inclusion criteria. This incidence is similar to that reported in the TRISCEND II clinical trial.•New AV block occurred in a median of 26 hours after Evoque TTVR (interquartile range: 5-60 hours), but there were cases of new AV block that occurred as late as 7 days after the procedure.•Of the 14 new cases of AV block, 12 were treated successfully with implantation of a leadless pacemaker (Micra) under fluoroscopic guidance without procedural complications or compromising the valve implantation.•The institutional strategy of 48-hour post-Evoque inpatient monitoring for all patients followed by mobile cardiac outpatient telemetry identified 11 of 14 cases of new AV block as before discharge from the hospital and 1 case as an outpatient before symptom onset.
PubMed ID
40822378
Volume
9
Issue
9
First Page
100701
Last Page
100701
